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Summary The bisphosphonate pamidronate (3 amino-I, 1-hydroxypropylidene bisphosphonate (APD), Ciba-
Geigy) is a powerful inhibitor of osteoclast function and has been shown to significantly reduce osteolysis
associated with bone metastases in breast cancer. Until recently, however, only an intravenous preparation has
been readily available. We have evaluated the toxicity and effect on urinary calcium excretion of an
enteric-coated oral preparation of pamidronate in a phase I/II trial in patients with bone metastases from
breast cancer. Sixteen women with progressive disease and evidence of active bone resorption with an elevated
calcium excretion (fasting urine calcium/creatinine ratio >0.4 (mmol mmol-') on two occasions prior to
treatment) were studied. Four were given 150 mg daily; four 300 mg daily; four 450 mg daily and four 600 mg
daily. Urinary calcium/creatinine (Ca2+/Cr) ratios were measured on all patients after an overnight fast. In
patients on 150mg daily the mean ratio fell from 0.65 (range 0.57-0.72) before treatment to 0.13 (0.02-0.19)
after three weeks treatment. Mean values at entry for patients on 300, 450 and 600 mg were 1.18 (0.72-2.1),
0.76 (0.42-1.5) and 0.63 (0.52-0.82) respectively and after treatment these fell to 0.11 (0.05-0.18), 0.37
(0.14-0.68) and 0.17 (0.06-0.25). There were no significant differences in efficacy between treatment groups.
Oral, enteric-coated disodium pamidronate is non-toxic and effectively reduces calcium excretion, raised in
association with metastatic bone disease at doses of 150mg or above. At the doses used to date it is as
effective as weekly treatments with 30 mg of the intravenous preparation. Further studies are required in order
to determine its value for preventing complications of bone disease and possibly as an adjuvant to surgery for
breast cancer.
The bisphosphonates are a class of compounds which are
enzyme resistant analogues of pyrophosphate, the naturally
occurring inhibitor of bone mineralisation. They are known
to bind to hydroxyapatite crystals, cause inhibition of osteo-
clast function and slow the rate of osteoclast mediated bone
resorption (Fleish, 1983). They are the treatment of choice
for the hypercalcaemia of malignancy, a syndrome charac-
terised, almost invariably, by excessive bone resorption and,
when used in combination with fluid replacement, are over
90% effective in restoring normocalcaemia (Morton et al.,
1988a; Jung et al., 1981). One early, placebo-controlled study
(van Holten-Verzantvoort et al., 1987) using a locally
manufactered oral APD preparation in combination with
standard treatment was encouraging, with a reduced
incidence of pathological fracture, hypercalcaemia and
requirement for radiotherapy at the sites of painful bone
lesions in the treated group. However, 8% of patients stop-
ped taking the drug because of gastrointestinal toxicity.
Recently there have been reports of the benefits of therapy
with intravenous pamidronate alone in patients with meta-
static bone disease (Morton et al., 1988b; Coleman et al.,
1988). They indicate that pamidronate given as two-weekly
infusions cause healing of lytic metastases in approximately
25% of patients and stablisation of disease in a further 25%.
It would be an advantage if pamidronate and other bisphos-
phonates could be given orally to circumvent the need for
repeated infusions and in view of this we have undertaken a
phase 1/2 dose-escalating study using a recently developed
enteric-coated formulation of oral pamidronate in women
with progressive skeletal breast cancer.
Methods
Sixteen women with metastatic breast cancer (Table I) with
documented progression in bone were treated with enteric-
coated oral pamidronate (Ciba-Geigy). Four patients were
given 150 mg daily; four 300 mg daily; four 450 mg daily and
four 600 mg daily. All had bone metastases confirmed by
isotope scintigraphy and plain radiology and all had evidence
of raised calcium excretion as measured by the ratio of
calcium to creatinine in fasting urine samples. All had
received therapy with at least one form of hormone treat-
ment and four had also received cytotoxic chemotherapy. In
women progressing on hormone treatment this was continued
to prevent confusion from a possible hormone withdrawal
response. During the first month of therapy women were seen
weekly and thereafter at monthly intervals. At each atten-
dance patients brought a fasting urine sample for estimation
of calcium and creatinine, routine serum biochemistry and
haematology were performed and patients were interviewed
with regard to potential toxicity and analgesic use. Dose
escalations were only made in the absence of major toxicity.
At the end of the four week study period in the absence of
adverse effects patients were continued on 300 mg daily.
Comparison was made between the effect on calcium excre-
tion of oral pamidronate with a similar group of 16 patients
treated with the intravenous preparation as previously de-
scribed (Morton et al., 1988b). Values for calcium/creatinine
ratio for all patients were subjected to a two way analysis of
variance to study differences between initial values and those
after treatment and also to determine if there was a
significant difference between treatment groups, i.e. a
dose-response effect.
Results
Effect on calcium excretion
The initial urinary calcium/creatinine ratios ranged from 0.42
to 2.1 (mean 0.8). There were no significant differences in the
initial values between patient groups. There was a significant
fall in calcium excretion at all doses of pamidronate. This fall
occurred within one week of treatment and tended to be
maximal by three weeks (Figure 1). In patients on 150mg
daily the mean ratio fell from 0.65 (range 0.57-0.72) before
treatment to 0.13 (0.02-0.19) after three weeks treatment.
Mean values at entry for patients on 300, 450 and 600 mg
were 1.18 (0.72-2.1), 0.76 (0.42-1.5) and 0.63 (0.52-0.82)
respectively and after treatment these fell to 0.11 (0.05-0.18),
0.37 (0.14-0.68) and 0.17 (0.06-0.25). There was little
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Table I Patientcharacteristics: age, dose ofpamidronate, disease freeinterval, type ofbone metastases, previous treatment,
and duration ofcurrent hormone treatment in thosepatients whose hormone treatment wascontinued throughout the study
period
Duration ofcurrent
Dose Age Disease-free Type ofbone Previous hormone treatment
Patient (mgday-') (years) interval (months) metastases treatment' (months)
1 150 57 108 mixed both N/A
2 150 51 13 lytic HT 10
3 150 51 28 mixed HT 23
4 150 42 22 lytic both 5
5 300 49 84 lytic HT N/A
6 300 78 120 lytic HT 46
7 300 41 26 mixed HT 5
8 300 51 20 lytic HT 8
9 450 57 70 mixed both 11
10 450 56 0 mixed HT 14
11 450 76 0 mixed HT 11
12 450 64 11 mixed HT 14
13 600 54 15 mixed both N/A
14 600 48 21 lytic HT 14
15 600 46 28 mixed HT N/A
16 600 52 31 mixed HT 16
'HT, hormone therapy; both, cytotoxics and hormone therapy.
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evidence of a dose-response effect. Since there were no
significant differences in Caa+/Cr ratios between the groups
the data from each were combined (Figure lb). There was a
highly significant fall in ratio after one week (0.8-0.37,
P<0.01) and a further fall in the mean value with a
minimum at week 3 (week 1 versus week 3, P<0.001).
In a previous study (Morton et al., 1988b) where pami-
dronate was given as a 2 h infusion of 30 mg each week there
was a fall of the Ca2+/Cr ratio from 0.85 to a minimum of
0.19 units (Figure 1c). There were no significant differences in
the fall of the Ca2+/Cr ratios of the combined 16 patients
treated with oral pamidronate compared with the 16 treated
with the intravenous preparation. At the end of the four
week study period all patients continued to take oral pami-
dronate at a dose of 300mg daily. The median subsequent
follow up time was 15 weeks (range 7-21 weeks). In twelve
patients the Ca2+/Cr ratios remained low. However, in four
patients there was progression of disease in bone despite
treatment and a rise of the mean ratio to pre-treatment levels
(Figure ld).
Toxicity
There was no gastrointestinal toxicity as doses of 150 mg and
300 mg daily. At 450 mg daily one out of four patients
experienced WHO grade 1 nausea and abdominal pain for 8
days one week after starting treatment. After dose reduction
to 300 mg this was abolished. At 600 mg daily one of four
patients required dose reduction because of similar gastro-
intestinal toxicity; she tolerated 300 mg daily without further
problems. Oral ulceration was not seen and there was no
haematological toxicity at any dose level. Two patients on
600 mg daily, developed asymptomatic hypocalcaemia (cor-
rected calcium 2.08 to 2.17 mmol '; normal range 2.2 to
2.65 mmol-1) one week after starting treatment which per-
sisted for one week in one patient and for two weeks in the
other.
Discussion
The bisphosphonates are absorbed poorly after oral adminis-
tration. Using radiolabelled pamidronate it is estimated that,
in rats, 2% of the oral dose is absorbed (Ciba-Geigy, data on
file). Estimates of the absorption of another bisphosphonate
(etidronate) range from 1 to 9% (Fogelman et al., 1986). The
effect of oral bisphosphonates on calcium release from bone
may however be assayed indirectly by estimating their effect
on the urinary Ca2+/Cr ratio. Our study indicates that oral
pamidronate does significantly inhibit calcium excretion.
Sufficient amounts are absorbed to give reductions in urinary
calcium/creatinine ratios equivalent to given the drug at a
dose of 30 mg weekly by the intravenous route.
The oral doses used were chosen to show a dose-response
effect. However, the effect of 150 mg daily was not
significantly different from the other three doses. It is
therefore possible that much lower doses will be effective and
further studies are required in order to determine the
minimum effective dose. Assuming 2% oral bioavailability,
21 mg of pamidronate would be absorbed per week at a dose
of 150 mg per day. This is a similar total weekly amount of
pamidronate given to patients in our previous study using
30 mg per week intravenously. The reduction in calcium
excretion was similar using the two routes of administration
and supports the conclusions from a study on tumour-
induced hypercalcaemia that the effect of pamidronate on the
reduction in serum calcium levels is largely unrelated to the
rate of its administration (Ralston et al., 1988). In this study
pamidronate was non-toxic. Only two patients developed
symptoms. These were mild epigastric discomfort which sub-
sided after the dose was lowered to 300 mg daily. Thus no
patient on 300 mg per day or a lower dose developed gastro-
intestinal toxicity and this compares favourably with the 8%
of patients who stopped using the drug because of toxicity in
the series reported by van Holten-Verzantvoort et al. (1987).
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Two patients developed mild hypocalcaemia; although
asymptomatic the significance of this needs to be addressed
in future studies where the drug is used for longer periods.
Pamidronate whether given orally or intravenously reduced
the increased calcium excretion associated with bone meta-
stases in all patients. However, in this study as with our
previous study, using intravenously administered drug, resis-
tance to pamidronate develops in a proportion of patients
after a few weeks. Since bisphosphonates are thought to act
by inhibition of tumour stimulated osteoclastic activity it is
likely that they would be inactive against metastases where
there is a direct bone destruction (Galasko, 1976). However,
this would not explain why calcium excretion was reduced in
all patients studied, albeit briefly in some.
In conclusion oral pamidronate is as effective as the intra-
venous preparation for reducing increased calcium excretion
associated with metastatic breast cancer to bone. Future
studies directed towards determining the minimum effective
dose, on long-term toxicity and on the place of pamidronate
combined with other therapeutic modalities in the manage-
ment of patients with bone metastases are indicated.
We would like to thank Ciba-Geigy Pharmaceuticals for supplies of
pamidronate and for financial support.
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